<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="86105">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984242</url>
  </required_header>
  <id_info>
    <org_study_id>WO29074</org_study_id>
    <secondary_id>2013-003167-58</secondary_id>
    <nct_id>NCT01984242</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma</brief_title>
  <acronym>IMmotion150</acronym>
  <official_title>A Phase II, Randomized Study of Atezolizumab (Anti PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, randomized, open-label study will evaluate the efficacy, safety and
      tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus
      sunitinib in participants with histologically confirmed, previously untreated locally
      advanced or metastatic renal cell carcinoma who have not received prior systemic therapy
      either in the adjuvant or metastatic setting.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1) via Central Independent Review Committee (IRC) Assessment in Intent-to-Treat (ITT) Population</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1) via Central IRC Assessment in Participants who Have Detectable PD-L1 Expression</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival per RECIST v.1.1 in Participants who Have Tumors With Higher Than Median Expression of an Immune Gene Signature</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival per RECIST v.1.1 in Participants who Have Tumors With Higher Than the 33rd Percentile Expression of an Immune Gene Signature</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival Using Investigator Assessment</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response (Complete + Partial Response [CR+PR]) per RECIST v1.1 Using Investigator Assessment</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response (CR+PR) per RECIST v1.1 via an Independent Central Radiologic Review</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Overall Response per Modified RECIST Using Investigator Assessment</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival per Modified RECIST Using Investigator Assessment</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response per RECIST v1.1 Criteria</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response per Modified RECIST Criteria</measure>
    <time_frame>From randomization until disease progression or death from any cause (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization up to death or study completion (Up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Crossover Treatment Phase Participants With a Best Overall Response of CR or PR</measure>
    <time_frame>From Day 1 of crossover Cycle 1 (cycle length=6 weeks) until disease progression or death from any cause (up to approximately 1.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response in Crossover Treatment Phase Participants</measure>
    <time_frame>From Day 1 of crossover Cycle 1 (cycle length=6 weeks) until disease progression or death from any cause (up to approximately 1.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival in Crossover Treatment Phase Participants</measure>
    <time_frame>From Day 1 of crossover Cycle 1 (cycle length=6 weeks) until disease progression or death from any cause (up to approximately 1.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From randomization until 30 days after last dose of study treatment (up to approximately 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Atezolizumab</measure>
    <time_frame>Pre-infusion (0 hour) (infusion duration = 60 minutes) on Day 1 of Cycles 1, 2, 4 and 8, thereafter every 8 cycles (each cycle = 6 weeks) until end of treatment visit (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Atezolizumab</measure>
    <time_frame>30 min post-infusion (infusion duration = 60 minutes) on Cycle 1 (cycle length = 6 weeks), Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Atezolizumab</measure>
    <time_frame>Pre-infusion (0 hour) on Day 1 of Cycles 1, 2, and 4; Day 22 of Cycles 1, 2, and 4 (each cycle = 6 weeks); and at study termination (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Bevacizumab</measure>
    <time_frame>30 min post-infusion (infusion duration = 90 minutes) on Day 1 of Cycles 1 and 2 (each cycle = 6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of Bevacizumab</measure>
    <time_frame>Pre-infusion (0 hour) (infusion duration = 60 minutes) on Day 1 of Cycles 1 and 2 (each cycle = 6 weeks), and at study termination (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M.D. Anderson Symptom Inventory (MDASI) Score</measure>
    <time_frame>From randomization up to end of treatment (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Fatigue Inventory (BFI) Score</measure>
    <time_frame>From randomization up to end of treatment (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimension Questionnaire (EQ-5D) Score</measure>
    <time_frame>From randomization up to end of treatment (up to approximately 2.5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>A: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab 1200 mg IV infusions q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants may crossover to receive atezolizumab + bevacizumab combination until disease progression, unacceptable toxicity, withdrawal from study, or study completion or termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Sunitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib 50 mg orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants (except EU participants) may crossover to receive atezolizumab + bevacizumab combination until disease progression, unacceptable toxicity, withdrawal from study, or study completion or termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>1200 mg IV q3w</description>
    <arm_group_label>A: Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_label>B: Atezolizumab</arm_group_label>
    <other_name>Tecentriq, MPDL3280A, RO5541267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg IV q3w</description>
    <arm_group_label>A: Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg orally once daily for 4 weeks, followed by 2 weeks of rest</description>
    <arm_group_label>C: Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable advanced or metastatic renal cell carcinoma with component of clear cell
             histology and/or component of sarcomatoid histology that has not been previously
             treated with any systemic agents, including treatment in the adjuvant setting

          -  Measurable disease, as defined by RECIST v1.1

          -  Karnofsky performance score greater than or equal to (&gt;/=) 70

          -  Adequate hematologic and end-organ function as defined by protocol

          -  Women of childbearing potential and male participants with partners of childbearing
             potential must agree to use highly effective methods of contraception as defined by
             protocol

        Exclusion Criteria:

        Disease-Specific Exclusions:

          -  Radiotherapy for renal cell carcinoma within 14 days prior to Cycle 1, Day 1 with the
             exception of: Single-fraction radiotherapy given for the indication of pain control

          -  Known active malignancies or metastasis of the brain or spinal cord or leptomeningeal
             disease, as determined by computed tomography (CT) or magnetic resonance imaging
             (MRI) evaluation during screening and prior radiographic assessments

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently)

          -  Uncontrolled hypercalcemia or symptomatic hypercalcemia

          -  Malignancies other than renal cell carcinoma within 5 years prior to Cycle 1, Day 1,
             with the exception of those with a negligible risk of metastasis or death, treated
             with expected curative outcome

        General Medical Exclusions:

          -  Life expectancy of less than (&lt;) 12 weeks

          -  Pregnant and lactating women

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest CT scan

          -  Participants with active or chronic hepatitis B, active hepatitis C, Human
             Immunodeficiency Virus (HIV) positive test, significant cardiovascular disease

          -  Prior allogeneic stem cell or solid organ transplant

        Exclusion Criteria Related to Medications:

          -  Prior treatment with Cluster of Differentiation 137 (CD137) agonists, anti-Cytotoxic
             T-Lymphocyte Antigen-4 (CTLA-4), anti-PD-1, or anti PD-L1 therapeutic antibody or
             pathway-targeting agents

          -  Treatment with systemic immunostimulatory agents for any reason within 6 weeks or
             five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1

          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle
             1, Day 1

        Bevacizumab- and Sunitinib-Specific Exclusions:

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina, stroke or transient ischemic
             attack within 3 months prior to Cycle 1, Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Oncology Hematology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Colorado Health Sci Ctr</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Ctr - Denver (Williams)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Uni School of Medicine; Section of Medical Oncology</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510-3289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown U; Lombardi Comp Can</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016-1468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI Florida Cancer Specialists South</name>
      <address>
        <city>Ft Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist, North Region</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Inst.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation; Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Associates of Oregon, P.C</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC - Nashville (20th Ave)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykova nemocnice Usti nad Labem</name>
      <address>
        <city>Ústí nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin; Oncologie Medicale.</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret; Cancerologie Urologie Digestive</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis; Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou; Service D'Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud; Departement Oncologie Medicale</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Departement Oncologie Medicale</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule; Zentrum Innere Medizin; Abt. Hämatologie u. Onkologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München; Klinikapotheke</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum d.Universität München Campus Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele; Medical Oncology</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology, Arezzo</name>
      <address>
        <city>Arezzo</city>
        <state>Toscana</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Med. Ostrobramska NZOZ Magodent</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. I. Chiricuta Institute of Oncology</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisprof SRL</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400058</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean de Urgenta Satu Mare</name>
      <address>
        <city>Satu Mare</city>
        <zip>440055</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp de Madrid Norte Sanchinarro; Centro Integral; Onco Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Clinico Univ Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Ctr NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust.</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
